Everything below concerns melanotan-2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-02. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Insulin degludec/liraglutide is a fixed-dose combination medication used to improve glycemic control in adults with type 2 diabetes, alongside diet and exercise. It consists of insulin degludec and liraglutide and is administered through subcutaneous injection. Gastrointestinal side effects include nausea, diarrhea, vomiting, constipation, dyspepsia (indigestion), gastritis (stomach inflammation), abdominal pain, flatulence, gastroesophageal reflux disease (acid reflux), and abdominal distension. Severe symptomatic hypoglycemia was reported in a small number of patients during clinical trials. Insulin degludec functions as a replacement insulin, facilitating glucose uptake into cells and thereby reducing the symptoms and complications of diabetes. It differs slightly from human insulin, as it is absorbed more gradually and consistently, allowing for prolonged action. Liraglutide, a GLP-1 receptor agonist, mimics the effects of incretin hormones by enhancing insulin secretion from the pancreas in response to food intake, thereby aiding blood glucose regulation. Insulin degludec/liraglutide is sold by Novo Nordisk under the name Xultophy.
=== Regulation === In the United States, the Food and Drug Administration (FDA) regulates nicotine as a tobacco product under the 2009 Family Smoking Prevention and Tobacco Control Act. The FDA is tasked with reviewing tobacco products such as e-cigarettes and determining which can be authorized for sale. In March 2022, the US Congress passed a law (the Consolidated Appropriations Act, 2022) that expanded FDA's tobacco regulatory authority to include tobacco products containing nicotine from any source, thereby including products made with synthetic nicotine. On January 17, 2025, the FDA proposed a strongly endorsed rule to reduce nicotine in cigarettes and certain combusted tobacco products to minimally or non-addictive levels, capping nicotine yield at 0.7 mg per gram of tobacco, approximately a 95% reduction from current commercial levels. In the European Union, the Tobacco Products Directive (2014/40/EU) regulates the manufacture, presentation, and sale of tobacco and related products. In the United Kingdom, the Tobacco and Related Products Regulations 2016 implemented the European directive 2014/40/EU, amended by Tobacco Products and Nicotine Inhaling Products (Amendment etc.) (EU Exit) Regulations 2019 and the Tobacco Products and Nicotine Inhaling Products (Amendment) (EU Exit) Regulations 2020. Additionally other regulations limit advertising, sale and display of tobacco products and other products containing nicotine for human consumption.
Kinetic Concepts, Inc., (KCI) was a global corporation that produced medical technology related to wounds and wound healing. KCI produced the first product developed specifically for negative pressure wound therapy. In 2013, the company employed 5,000 people and marketed its products in more than 25 countries. Its headquarters were in San Antonio, Texas. KCI, LifeCell and Systagenix operated under the Acelity brand. In October 2019, Acelity and its KCI subsidiaries worldwide were acquired by 3M for $6.7 billion, including assumption of debt and other adjustments.
=== Refrigeration === Around 1938, following a request by Numero, Jones began designing the Thermo Control Model A automatic truck refrigeration unit. Jones designed the portable air-cooling unit for trucks carrying perishable food to prevent spoilage. The Model A refrigeration equipment was attached to undercarriages of trucks. Chilled air was transported to the inside of the trailer via refrigerant tubing. Because Model A was too heavy, Jones later developed the Model B, which was smaller and lighter, but not durable. In 1941, Jones completed development of the Model C, which was mounted to the front of the truck, was compact, light, and withstood road travel vibrations. In 1939, Jones filed for a patent for the Model A and received a patent for it on July 12, 1949. Numero sold his movie sound equipment business to RCA and formed a new company in partnership with Jones, the U.S. Thermo Control Company (later the Thermo King Corporation) which became a $3 million business by 1949. Portable cooling units designed by Jones were especially important during World War II, preserving blood, medicine, and food for use at army hospitals and on open battlefields. Model C units were initially manufactured for military use, but following the war the units became available for commercial use as well.
In 2001, Freeman reprised his role of Alex Cross in Along Came a Spider, a sequel to 1997's Kiss the Girls. The film received mixed-to-negative reviews. Susan Wloszczyna of USA Today observed that "Freeman strides with noble authority" but thought the overall film was unmemorable. In 2002, Freeman was cast opposite Ben Affleck in the spy thriller The Sum of All Fears. It is based on Tom Clancy's 1991 novel of the same name, about a plot by an Austrian Neo-Nazi to trigger a nuclear war between the United States and Russia, so that he can establish a fascist superstate in Europe. The Sum of All Fears received moderate reviews, but was a commercial success, grossing $193.9 million worldwide. Next, Freeman starred alongside Ashley Judd and Jim Caviezel in High Crimes (2002), a legal thriller based on Joseph Finder's 1998 novel of the same name. The story follows lawyer Claire (Judd), whose husband (Caviezel) is arrested and placed on trial for the murder of villagers while he was in the Marines. Although several critics were unimpressed with the story, they credited Freeman and Judd for their chemistry and performances. In 2003, Freeman appeared as God in the hit comedy Bruce Almighty with Jim Carrey and Jennifer Aniston. Next, he starred in the science fiction horror Dreamcatcher, adapted from Stephen King's 2001 novel of the same name. The film was a box-office flop, and garnered mostly negative reviews; Dreamcatcher has an approval rating of 28% on review aggregate site Rotten Tomatoes.
Sources: en.wikipedia.org
Tight scaly skin (Ichthyosis) Absence of ABCA12 gene (Ichthyosis) Swollen or puffy gums (Periodontitis/Gingivitis) Purulent drainage from lips (Improper Wound healing) Wide mouth which causes difficulty feeding and suckling Difficulty in feeding causes lack of adequate nutrition, dehydration and even death Skin that is more prone to infection Hindered pulmonary ventilation Hindered pulmonary ventilation
=== Solo & local === Since the diffusion of Ca2+ in the cell is spatially restricted, Ca2+ released by a channel does not travel far from its source (the channel mouth) — model estimates are in the 50 nm range. Therefore, the small total amount of Ca2+ released from lysosomal channels will form locally high [Ca2+] domains around the cytosolic face of lysosomal Ca2+ channels. By strategic placement of Ca2+-sensitive decoding proteins within these domains (e.g. in a complex with the channel), local Ca2+ signals can stimulate Ca2+-dependent events — crucially, even in the absence of a global cytosolic Ca2+ signal. This is the modality when lysosomes are acting on their own. The NAADP/TPC axis has been reported to exhibit such signal compartmentation, such local Ca2+ signalling, in different physiological settings. In other words, this local modality can explain why some processes are driven uniquely by NAADP/TPCs rather than other Ca2+ signalling pathways. For example, NAADP/TPCs are unique drivers of cell killing by Cytotoxic T cells. Similarly, phagocytosis via the Fc receptor in the macrophage is driven only by highly local Ca2+ domains generated by NAADP/TPCs (whereas the global ER Ca2+ signals play no role). This unique dependence is not restricted to immune cells, but is also observed in neurons during long-term potentiation, and neuronal differentiation. Angiogenesis is another NAADP/TPC-dependent pathway.
==== Joint injections ==== Intra-articular injections of steroids, hyaluronic acid, or platelet-rich plasma may be used for pain relief in people with knee osteoarthritis. Local drug delivery by intra-articular injection may be more effective and safer in terms of increased bioavailability, less systemic exposure and reduced adverse events. Several intra-articular medications for symptomatic treatment are available.
NAD bound to proteins in the Protein Data Bank NAD Animation (Flash Required) β-Nicotinamide adenine dinucleotide (NAD+, oxidized) and NADH (reduced) Chemical data sheet from Sigma-Aldrich NAD+, NADH and NAD synthesis pathway at the MetaCyc database List of oxidoreductases Archived 30 November 2010 at the Wayback Machine at the SWISS-PROT database NAD+
Sources: en.wikipedia.org
Pyrimidine oxygenase (EC 1.14.99.46, gene RutA) is an enzyme characterised from Escherichia coli with systematic name uracil,FMNH2:oxygen oxidoreductase (uracil hydroxylating, ring-opening). It catalyses two related oxidation reactions which act on pyrimidine nucleobases. The overall effect of the first example is to convert uracil to (Z)-3-ureidoacrylic acid with molecular oxygen as the oxidant and flavin mononucleotide (FMN) as a cofactor. The enzyme also requires nicotinamide adenine dinucleotide (NADH):
== Gingival fibers and periodontitis == In theory, gingival fibers are the protectors against periodontitis, as once they are breached, they cannot be regenerated. When destroyed, the gingival sulcus (labelled G in the diagram) increases in depth apically, allowing more debris and bacteria to remain in intimate contact with the delicate sulcular and junctional epithelia for longer times.
== External links == Allozyme Electrophoresis Techniques – a complete guide to starch gel electrophoresis Development of new isozyme specific therapeutics – Fatty Acid Dioxygenases and Eicosanoid Hormones (Estonia)
These games have no use, and they are harmful and a waste of time.” In 2016, Saleh al-Fawzan has issued other rulings that have drawn attention in Western media, including a fatwa reportedly prohibiting the mobile game Pokémon Go, which he classified as a form of gambling. He has also been reported to consider photography generally prohibited except when necessary. In 2017, he was reported to have referred to Shia Muslims as "brothers of Satan" and stated that they are "infidels" who "lie about God, his prophet, and the consensus of Muslims", remarks that have been cited as an example of sectarian rhetoric among some Saudi clerics. Al-Fawzan's supporters argue that his statements reflect traditional jurisprudence and adherence to Salafi teachings while critics contend that his pronouncements promote intolerance and discourage reform.
Using ICT, a technician can make a determination at a patient's bedside, without the need for a laboratory. ICT detection is highly specific to the microbe causing an infection. Immunoaffinity chromatography has been applied to the selective isolation of blood-derived components, including lymphocytes and specific proteins, using antibody-functionalized stationary phases. Although not a routine method for estimating the time since deposition (TSD) of bloodstains, targeted molecular analyses used in TSD research – such as proteomics, metabolomics, and nucleic-acid profiling – may incorporate immunoaffinity-based enrichment steps to improve sensitivity for low-abundance biomarkers. Antibody-based detection methods are also used in forensic serology to identify blood and evaluate its persistence on substrates over time, demonstrating the broader role of immunological specificity in forensic body-fluid analysis.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.